These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 7690418)

  • 1. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
    Moore JP; Sattentau QJ; Yoshiyama H; Thali M; Charles M; Sullivan N; Poon SW; Fung MS; Traincard F; Pinkus M
    J Virol; 1993 Oct; 67(10):6136-51. PubMed ID: 7690418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
    Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
    J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
    J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
    Moore JP; Sattentau QJ; Wyatt R; Sodroski J
    J Virol; 1994 Jan; 68(1):469-84. PubMed ID: 7504741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.
    Shotton C; Arnold C; Sattentau Q; Sodroski J; McKeating JA
    J Virol; 1995 Jan; 69(1):222-30. PubMed ID: 7527084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
    Wu Z; Kayman SC; Honnen W; Revesz K; Chen H; Vijh-Warrier S; Tilley SA; McKeating J; Shotton C; Pinter A
    J Virol; 1995 Apr; 69(4):2271-8. PubMed ID: 7533854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
    McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
    J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
    J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
    Pinter A; Honnen WJ; He Y; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2004 May; 78(10):5205-15. PubMed ID: 15113902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    Fung MS; Sun CR; Gordon WL; Liou RS; Chang TW; Sun WN; Daar ES; Ho DD
    J Virol; 1992 Feb; 66(2):848-56. PubMed ID: 1370558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
    Doran RC; Morales JF; To B; Morin TJ; Theolis R; O'Rourke SM; Yu B; Mesa KA; Berman PW
    Mol Immunol; 2014 Nov; 62(1):219-226. PubMed ID: 25016576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
    Ho DD; Fung MS; Cao YZ; Li XL; Sun C; Chang TW; Sun NC
    Proc Natl Acad Sci U S A; 1991 Oct; 88(20):8949-52. PubMed ID: 1717992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.
    McKnight A; Shotton C; Cordell J; Jones I; Simmons G; Clapham PR
    J Virol; 1996 Jul; 70(7):4598-606. PubMed ID: 8676486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Broder CC; Earl PL; Long D; Abedon ST; Moss B; Doms RW
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11699-703. PubMed ID: 7972127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.